Browsing ICR Divisions by title
Now showing items 4021-4040 of 4607
-
Targeting aneuploidy, CIN and mechanisms of DNA content reduction in cancer
(Institute of Cancer Research (University Of London), 2021-02-28)Chromosomal instability (CIN) and aneuploidy are distinct events that can coexist in a tumour and one can result from the other. They can arise through direct errors in mitosis or in DNA damage repair and response machineries, ... -
Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions.
(2017-01)Colorectal cancer (CRC) is one of the commonest cancers in the world. During the last decade, the development of targeted therapies has given cancer treatment a novel direction in management of metastatic CRC (mCRC) and ... -
Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
(AMER ASSOC CANCER RESEARCH, 2018-07-01)Purpose: Persistent androgen receptor (AR) signaling drives castration-resistant prostate cancer (CRPC) and confers resistance to AR-targeting therapies. Novel therapeutic strategies to overcome this are urgently required. ... -
Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides.
(CELL PRESS, 2021-01-11)Accumulating preclinical and clinical evidence indicates that high degrees of heterogeneity among malignant cells constitute a considerable obstacle to the success of cancer therapy. This calls for the development of ... -
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.
(BMJ PUBLISHING GROUP, 2022-01-01)BACKGROUND: Preclinical data suggest that concurrent treatment of anti-CD38 and antiprogrammed death 1 (PD-1)/programmed death ligand 1 (PD-L1) antibodies substantially reduce primary tumor growth by reversing T-cell ... -
Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.
(2016-09)Background In synovial sarcomas alterations in the cyclin D1-CDK4/6-Rb axis have been described. Also, β-catenin, a cyclin D1 regulator, is often overexpressed. Additionally, studies have shown that the t(X;18) translocation ... -
Targeting cyclooxygenase by indomethacin decelerates progression of acute lymphoblastic leukemia in a xenograft model.
(AMER SOC HEMATOLOGY, 2019-11-12)Acute lymphoblastic leukemia (ALL) develops in the bone marrow in the vicinity of stromal cells known to promote tumor development and treatment resistance. We previously showed that the cyclooxygenase (COX) inhibitor ... -
Targeting deficient DNA damage repair in gastric cancer.
(2016-09)Introduction Over recent years our understanding of DNA damage repair has evolved leading to an expansion of therapies attempting to exploit DNA damage repair deficiencies across multiple solid tumours. Gastric cancer has ... -
Targeting DNA damage response in oesophagogastric cancers
(Institute of Cancer Research (University Of London), 2023-05-30)A subset of patients with oesphophagogastric (OG) adenocarcinomas are characterised by homologous recombination repair deficiency (HRD), providing the rationale for poly (ADP-ribose) polymerase inhibitor (PARPi) therapy ... -
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
(2017-01)Germline aberrations in critical DNA-repair and DNA damage-response (DDR) genes cause cancer predisposition, whereas various tumors harbor somatic mutations causing defective DDR/DNA repair. The concept of synthetic lethality ... -
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer.
(SPRINGERNATURE, 2019-03-08)Inframe insertions of three or more base pairs in exon 20 of the epidermal growth factor receptor (EGFR) gene were among the first EGFR mutations to be identified as oncogenic drivers in non-small cell lung cancer (NSCLC). ... -
Targeting Endo180 with an antibody-drug conjugate for cancer treatment
(Institute of Cancer Research (University Of London), 2024-03-22)Antibody-drug conjugates (ADCs) are formed of an antibody attached to a cytotoxic drug via a linker which is cleaved upon internalisation of the ADC into the cell. This allows very toxic drugs to be directed to specific ... -
Targeting folate receptor alpha for cancer treatment.
(IMPACT JOURNALS LLC, 2016-08-09)Promising targeted treatments and immunotherapy strategies in oncology and advancements in our understanding of molecular pathways that underpin cancer development have reignited interest in the tumor-associated antigen ... -
Targeting HOX/PBX dimers in cancer.
(IMPACT JOURNALS LLC, 2017-05-09)The HOX and PBX gene families encode transcription factors that have key roles in establishing the identity of cells and tissues in early development. Over the last 20 years it has become apparent that they are also ... -
Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome.
(OXFORD UNIV PRESS INC, 2018-01-01)Oxygen deprivation (hypoxia) in non-small cell lung cancer (NSCLC) is an important factor in treatment resistance and poor survival. Hypoxia is an attractive therapeutic target, particularly in the context of radiotherapy, ... -
Targeting molecular addictions in cancer.
(NATURE PUBLISHING GROUP, 2014-11-25)Cancer cells depend on a finite number of critical signals for their survival. Oncogene addiction, that is, the acquired dependence of a cancer cell on the activity of a single oncogenic gene product, has been the basis ... -
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.
(NATURE PORTFOLIO, 2023-11-30)Inflammation is a hallmark of cancer1. In patients with cancer, peripheral blood myeloid expansion, indicated by a high neutrophil-to-lymphocyte ratio, associates with shorter survival and treatment resistance across ... -
Targeting NaPi2b in ovarian cancer.
(ELSEVIER SCI LTD, 2023-01-01)Novel biomarkers are needed to direct new treatments for ovarian cancer, a disease for which the standard of care remains heavily focused on platinum-based chemotherapy. Despite the success of PARP inhibitors, treatment ... -
Targeting of Ras-mediated FGF signaling suppresses Pten-deficient skin tumor.
(2016-11)Deficiency in PTEN (phosphatase and tensin homolog deleted on chromosome 10) is the underlying cause of PTEN hamartoma tumor syndrome and a wide variety of human cancers. In skin epidermis, we have previously identified ... -
Targeting PIK3CA-mutant advanced breast cancer in the clinical setting.
(ELSEVIER SCIENCE INC, 2017-07-01)